Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan H M Schellens

Showing results (1-10 of 541) with videos related to

Pageof 55
Sort By:
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Challenges of oral chemotherapyJan H M Schellens
Basic & Clinical Pharmacology & Toxicology|November 22, 2007
Looking back at EACPT 2007Jan H M Schellens
The Oncologist|February 14, 2007
CapecitabineJan H M Schellens
European Journal of Cancer (Oxford, England : 1990)|February 24, 2009
Phase 0 (zero) clinical trials: more than zero benefit?Jan H M Schellens
JAMA Oncology|October 28, 2016
Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effect-ReplyJan H M Schellens
The New England Journal of Medicine|April 7, 2017
Clinical Trials Series — Large PharmaJan H M Schellens, René Bernards
The Lancet. Oncology|August 4, 2004
Drug interactions in oncologyJos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Personalized medicine in oncology: a personal view with myths and factsJos H Beijnen, Jan H M Schellens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Endostatin: are the 2 years up yet?Jan H M Schellens, Mark J Ratain
Current Clinical Pharmacology|May 11, 2010
Selected new developments in oncologyJos H Beijnen, Jan H M Schellens
Pageof 55

Showing results (1-10 of 541) with videos related to

Sort By:
Pageof 55
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
Challenges of oral chemotherapyJan H M Schellens
Basic & Clinical Pharmacology & Toxicology|November 22, 2007
Looking back at EACPT 2007Jan H M Schellens
The Oncologist|February 14, 2007
CapecitabineJan H M Schellens
European Journal of Cancer (Oxford, England : 1990)|February 24, 2009
Phase 0 (zero) clinical trials: more than zero benefit?Jan H M Schellens
JAMA Oncology|October 28, 2016
Potential Benefit of Low-Dose Candesartan in Trastuzumab-Induced Cardiotoxic Effect-ReplyJan H M Schellens
The New England Journal of Medicine|April 7, 2017
Clinical Trials Series — Large PharmaJan H M Schellens, René Bernards
The Lancet. Oncology|August 4, 2004
Drug interactions in oncologyJos H Beijnen, Jan H M Schellens
Current Clinical Pharmacology|April 22, 2010
Personalized medicine in oncology: a personal view with myths and factsJos H Beijnen, Jan H M Schellens
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Endostatin: are the 2 years up yet?Jan H M Schellens, Mark J Ratain
Current Clinical Pharmacology|May 11, 2010
Selected new developments in oncologyJos H Beijnen, Jan H M Schellens
Pageof 55